Literature DB >> 32184594

Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.

Lu Hou1,2, Zheyu Song3, Zhonghang Xu3, Yuanyu Wu3, Wei Shi1,2.   

Abstract

BACKGROUND: siRNA-mediated polo-like kinase 1 (PLK1) silencing has been proposed as a promising therapeutic method for multiple cancers. However, the clinic application of this method is still hindered by the low specific delivery of siPLK1 to desired tumor lesions. Herein, folate (FA)-modified and leucine-bearing polyethylenimine was successfully synthesized and showed excellent targeted silencing to folate receptor overexpressed cells.
MATERIALS AND METHODS: The condensation of siPLK1 by FA-N-Ac-L-Leu-PEI (NPF) was detected by the gel retardation assay. The targeted and silencing efficiency was evaluated by flow cytometry and confocal laser scanning microscope. The PLK1 expressions at gene or protein levels were detected by quantitative real-time PCR and Western blotting assay. Further impacts of the PLK1 silencing on cell viability, cell cycle, migration, and invasion were studied by MTT, colony formation, wound healing and transwell assays.
RESULTS: The NPF and siPLK1 could efficiently assemble to stable nanoparticles at a weight ratio of 3.0 and showed excellent condensation and protection effect. Owing to the FA-mediated targeted delivery, the uptake and silencing efficiency of NPF/siPLK1 to SGC-7901 cells was higher than that without FA modification. Moreover, NPF-mediated PLK1 silencing showed significant antitumor activity in vitro. The anti-proliferation effect of PLK1 silencing was induced via the mitochondrial-dependent apoptosis pathway with the cell cycle arrest of 45% at G2 phase and the apoptotic ratio of 28.3%.
CONCLUSION: FA-N-Ac-L-Leu-PEI (NPF) could generate targeted delivery siPLK1 to FA receptor overexpressed cells and dramatically downregulate the expression of PLK1 expression.
© 2020 Hou et al.

Entities:  

Keywords:  folate; gene therapy; leucine-bearing PEI; siPLK1; targeted delivery

Mesh:

Substances:

Year:  2020        PMID: 32184594      PMCID: PMC7060029          DOI: 10.2147/IJN.S227289

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  32 in total

1.  Clonogenic assay of cells in vitro.

Authors:  Nicolaas A P Franken; Hans M Rodermond; Jan Stap; Jaap Haveman; Chris van Bree
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 2.  Polo-like kinases: a team in control of the division.

Authors:  Barbara C M van de Weerdt; René H Medema
Journal:  Cell Cycle       Date:  2006-04-17       Impact factor: 4.534

3.  Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.

Authors:  Birgit Spänkuch-Schmitt; Jürgen Bereiter-Hahn; Manfred Kaufmann; Klaus Strebhardt
Journal:  J Natl Cancer Inst       Date:  2002-12-18       Impact factor: 13.506

4.  PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes.

Authors:  Kristin A Greco; Carrie A Franzen; Kimberly E Foreman; Robert C Flanigan; Paul C Kuo; Gopal N Gupta
Journal:  Urology       Date:  2016-02-12       Impact factor: 2.649

5.  Ternary complexes of folate-PEG-appended dendrimer (G4)/α-cyclodextrin conjugate, siRNA and low-molecular-weight polysaccharide sacran as a novel tumor-selective siRNA delivery system.

Authors:  Ayumu Ohyama; Taishi Higashi; Keiichi Motoyama; Hidetoshi Arima
Journal:  Int J Biol Macromol       Date:  2017-02-14       Impact factor: 6.953

6.  Receptor and Microenvironment Dual-Recognizable Nanogel for Targeted Chemotherapy of Highly Metastatic Malignancy.

Authors:  Jinjin Chen; Jianxun Ding; Weiguo Xu; Tianmeng Sun; Haihua Xiao; Xiuli Zhuang; Xuesi Chen
Journal:  Nano Lett       Date:  2017-06-26       Impact factor: 11.189

7.  Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model.

Authors:  Alexander Ewe; Sabrina Höbel; Claudia Heine; Lea Merz; Sonja Kallendrusch; Ingo Bechmann; Felicitas Merz; Heike Franke; Achim Aigner
Journal:  Drug Deliv Transl Res       Date:  2017-04       Impact factor: 4.617

Review 8.  Targeting polo-like kinase 1 for cancer therapy.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

9.  MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.

Authors:  J Wang; D H Kho; J-Y Zhou; R J Davis; G S Wu
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

10.  Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.

Authors:  Yonghuan Mao; Ling Xi; Quan Li; Zeling Cai; Yimei Lai; Xinhua Zhang; Chunzhao Yu
Journal:  Oncol Rep       Date:  2016-05-18       Impact factor: 3.906

View more
  1 in total

1.  Phenylboronic Acid-Modified Polyamidoamine Mediated the Transfection of Polo-Like Kinase-1 siRNA to Achieve an Anti-Tumor Efficacy.

Authors:  Gu Gong; Xiuhui Tang; Jiayuan Zhang; Xiao Liang; Jiebing Yang; Quanshun Li
Journal:  Int J Nanomedicine       Date:  2021-12-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.